Acute respiratory distress syndrome (ARDS) is the main cause for the COVID-19 infection-
related morbidity and mortality. Recent clinical evidences suggest increased level of …

Abstract Interleukin (IL)‐1 receptor antagonist (IL‐1Ra), a naturally occurring antagonist of IL‐
1α/IL‐1β signaling pathways, has been attributed to the immunosuppressive effects of …

Objective To test whether autologous modified mesenchymal stem cells (MSCs) improve
recovery in patients with chronic major stroke. Methods In this prospective, open-label …

The emergence of the global pandemic caused by the novel SARS-CoV-2 virus has
motivated scientists to find a definitive treatment or a vaccine against it in the shortest …

The novel coronavirus severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) is
responsible for COVID-19 infection. The COVID-19 pandemic represents one of the worst …

Background The use of umbilical cord mesenchymal stem cells (UC-MSCs) is a burgeoning
method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory …

The mortality rate of critically ill patients with acute respiratory distress syndrome (ARDS) is
30.9% to 46.1%. The emergence of the coronavirus disease 2019 (Covid-19) has become a …

Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory
conditions have highlighted the significant benefit to patients who respond to MSC …

Abstract Coronavirus disease 2019 (COVID-19), a pandemic disease caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV2), is growing at an exponential rate …

To the Editor, We read with interest the article by Abraham and Krasnodembskaya regarding
mesenchymal stem cells (MSCs)-derived extracellular vesicles for the treatment of acute …